Chester County News and Community Website
WILMINGTON, DE — AstraZeneca’s Imfinzi combined with Amgen’s tarlatamab significantly extended overall survival in a Phase III trial of first-line extensive-stage small cell lung cancer, potentially expanding treatment options for …
AstraZeneca Lung Cancer Combo Extends Survival in Phase III Read More WILMINGTON, DE — AstraZeneca’s experimental COPD drug tozorakimab reduced moderate and severe exacerbations by as much as 34% in two Phase III trials across a broad patient population, supporting a …
AstraZeneca COPD Drug Cuts Exacerbations in Phase III Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) selected the 200-mcg dose of its SkinJect patch for further development after completing a Phase 2 basal cell carcinoma study, supporting the …
ISYMI: Medicus Picks 200-Mcg SkinJect Dose for Gorlin Program Read More
WILMINGTON, DE — Prelude Therapeutics Inc. (Nasdaq: PRLD) received U.S. Food and Drug Administration clearance to begin a Phase 1 trial of PRT13722, moving its experimental KAT6A-targeting breast cancer drug …
Prelude Wins FDA Clearance to Move Breast Cancer Drug to Trial Read More
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has dosed the first patient in a Phase 1 trial of CT-202, moving its Nectin-4 x CD3 bispecific antibody into human testing …
Context Therapeutics Starts Phase 1 Trial of CT-202 Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) received FDA authorization to begin an NDA-enabling Phase 2b study of SkinJect in patients with Gorlin Syndrome, advancing the company’s lead program …
FDA Clears Medicus SkinJect Study for Gorlin Syndrome Read More
MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has dosed the first patient in a global Phase 3 trial of OCU410, moving its one-time gene therapy for geographic atrophy into pivotal …
Malvern’s Ocugen Starts Pivotal Trial for Eye Gene Therapy Read More
PHILADELPHIA, PA — iECURE’s experimental gene-editing therapy reduced the annualized rate of life-threatening metabolic crises by 74% in the low-dose cohort of an early-stage trial in infants with severe ornithine …
iECURE Gene Therapy Cuts Severe Metabolic Crises in Trial Read More WILMINGTON, DE — AstraZeneca and Amgen’s TEZSPIRE met both primary endpoints in a Phase III trial of patients with eosinophilic esophagitis, extending the drug’s efficacy into a third inflammatory disease …
AstraZeneca, Amgen Drug Hits Phase III EoE Goals Read More
YARDLEY, PA — Savara Inc. (Nasdaq: SVRA) will present long-term efficacy and safety findings from its Phase 3 molgramostim trial Sept. 6 at the European Respiratory Society Congress in Barcelona, …
Savara Builds Molgramostim Case With Long-Term Trial Data Read More